Latest Key Developments (Source: Significant Developments)
MRI Interventions Inc's ClearPoint System Helps Advance Brain Cancer Clinical Trial of investigational Gene Therapy Drug Toca 511, Demonstrates Benefits Of MRI-Guided Drug Delivery
MRI Interventions Inc announced that its ClearPoint Neuro Intervention System is advancing the minimally-invasive precision delivery of the investigational gene therapy drug Toca 511 into malignant brain tumors. The procedure is being performed under real-time visualization and direct magnetic resonance imaging (MRI) guidance at select clinical trial sites. Highlights of the ClearPoint System's application in the Toca 511 trial include: Improved flow rates during drug delivery. The recently-introduced SmartFlow large-bore cannula increases the drug delivery rate threefold over documented flow rates of the original SmartFlow cannula. Like the original SmartFlow cannula, the new cannula incorporates a stepped tip design to prevent reflux and leakage of the drug outside of the target area, but the new cannula's large bore allows for a clinically meaningful increased rate of delivery. Precise delivery of the therapeutic agent into the brain tumor. Direct visualization of the procedure in real-time allows surgeons to monitor and confirm delivery to the tumor of Toca 511 mixed with MRI contrast agent at the time of infusion. Multiple trajectories in a single case. The ClearPoint System includes a SmartFrame targeting device that works with software to allow convenient repositioning of the cannula for multiple trajectories in a single case, and an adjustable head stabilization device that accommodates a wide range of possible entry points. Full Article
MRI Interventions, Inc. Completes $6 Million Financing
MRI Interventions, Inc. announced that it has completed a private placement equity financing. In the financing, MRI Interventions received gross proceeds of $6 million from the sale of approximately 5.45 million units at a purchase price of $1.10 per unit. Each unit consists of one share of MRI Interventions' common stock and one warrant to purchase 0.5 share of MRI Interventions' common stock. The warrants will be exercisable for a five-year period and have an exercise price of $1.45 per share. Pricing for the financing was set by the Company on June 25. Proceeds from the private placement will be used for general corporate and working capital purposes. Full Article
MRI scans could make baby autopsies more acceptable
* Distraught parents often refuse autopsy when a baby dies
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
